Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$955 Mln
Revenue (TTM)
$104 Mln
Net Profit (TTM)
$-168 Mln
ROE
-1.8 %
ROCE
-- %
P/E Ratio
--
P/B Ratio
56.4
Industry P/E
54.26
EV/EBITDA
0
Div. Yield
0 %
Debt to Equity
-1.5
Book Value
$--
EPS
$-5.1
Face value
--
Shares outstanding
33,813,700
CFO
$-237.64 Mln
EBITDA
$-393.21 Mln
Net Profit
$-419.19 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Intersect ENT (XENT)
| 3.4 | 1.1 | 3.3 | 60.3 | 0.9 | 4.1 | -- |
|
BSE Sensex*
| -13.4 | -9.8 | -13.9 | -3.6 | 7.5 | 7.9 | 11.2 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2021
|
2020
|
2019
|
2018
|
2017
|
2016
|
2015
|
|---|---|---|---|---|---|---|---|
|
Intersect ENT (XENT)
| 19.3 | -8.0 | -11.6 | -13.0 | 167.8 | -46.2 | 21.3 |
|
S&P Small-Cap 600
| 25.3 | 9.6 | 20.9 | -9.7 | 11.7 | 24.7 | -3.4 |
|
BSE Sensex
| 22.0 | 15.8 | 14.4 | 5.9 | 27.9 | 1.9 | -5.0 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Intersect ENT, Inc. operates as an ear, nose, and throat (ENT) medical technology company in the United States. The company offers PROPEL, a steroid releasing implant to open the surgically enlarged sinus; PROPEL Mini, a releasing implant to treat... patients undergoing frontal sinus surgery; and PROPEL Contour, a steroid releasing implant for the treatment of frontal and maxillary sinus ostia, or openings, of the dependent sinuses. It also provides SINUVA, a steroid releasing implant for the treatment of patients in the physician office setting; VENSURE Navigable and Stand-alone balloon, a sterile and single-use device, used to access and treat frontal, sphenoid sinus, and maxillary ostia in adults using a trans-nasal approach; and CUBE Navigation System, a virtual guidance platform for high precision ENT and ENT related skull-base surgeries. The company was formerly known as Sinexus, Inc. and changed its name to Intersect ENT, Inc. in November 2009. Intersect ENT, Inc. was incorporated in 2003 and is headquartered in Menlo Park, California. Read more
Pres, CEO & Director
Mr. Thomas A. West
Pres, CEO & Director
Mr. Thomas A. West
Headquarters
Menlo Park, CA
Website
Our rating system has guided millions of investors in the past 20 years.
The share price of Intersect ENT Inc (XENT) is $28.24 (NASDAQ) as of 13-May-2022 09:30 EDT. Intersect ENT Inc (XENT) has given a return of 0.91% in the last 3 years.
Since, TTM earnings of Intersect ENT Inc (XENT) is negative, P/E ratio is not available.
The P/B ratio of Intersect ENT Inc (XENT) is 56.40 times as on 13-May-2022, a 1812 premium to its peers’ median range of 2.95 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2021
|
-5.65
|
-13.05
|
|
2020
|
-10.45
|
11.28
|
|
2019
|
-17.95
|
6.54
|
|
2018
|
-36.88
|
6.99
|
|
2017
|
-57.42
|
8.02
|
The 52-week high and low of Intersect ENT Inc (XENT) are Rs -- and Rs -- as of 03-Apr-2026.
Intersect ENT Inc (XENT) has a market capitalisation of $ 955 Mln as on 13-May-2022. As per SEBI classification, it is a Small Cap company.
Before investing in Intersect ENT Inc (XENT), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.